Search Press releases Keywords From To 3 Mar 2026 UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody Read More 26 Feb 2026 Strong Execution Fueling Sustained Company Growth Read More 4 Feb 2026 UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements Read More 30 Jan 2026 KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d) Read More 13 Jan 2026 Innovation and Execution Power UCB’s Success Read More 8 Dec 2025 UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 1 of 60 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
